

1 **TITLE**

2 **RNA landscape of the emerging cancer-associated microbe**

3 ***Fusobacterium nucleatum***

4 **AUTHOR LIST**

5 Falk Ponath¹, Caroline Tawk², Yan Zhu², Lars Barquist^{1,3},

6 Franziska Faber², Jörg Vogel^{1,2,3*}

7

8 **AFFILIATIONS**

9 ¹ Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz Centre for
10 Infection Research (HZI), D-97080 Würzburg, Germany

11 ² Institute for Molecular Infection Biology (IMIB), University of Würzburg, D-97080
12 Würzburg, Germany

13 ³ Faculty of Medicine, University of Würzburg, Würzburg, Germany.

14

15 *Correspondence: joerg.vogel@uni-wuerzburg.de

16

17 Running title: RNA landscape of *Fusobacterium*

18

19 Keywords: Transcriptional start site, differential RNA-seq, noncoding RNA, antisense
20 RNA, small RNA, CRISPR/Cas, post-transcriptional control

21 **ABSTRACT**

22 *Fusobacterium nucleatum*, long known as a constituent of the oral microflora, has recently
23 garnered renewed attention for its association with several different human cancers. The
24 growing interest in this emerging cancer-associated bacterium contrasts with a paucity
25 of knowledge about its basic gene expression features and physiological responses. As
26 fusobacterial lack all established small RNA-associated proteins, post-transcriptional
27 networks in these bacteria are also unknown. Here, using differential RNA-seq (dRNA-
28 seq), we generate high-resolution global RNA maps for five clinically relevant
29 fusobacterial strains - *F. nucleatum* subspecies *nucleatum*, *animalis*, *polymorphum* and
30 *vincentii* as well as *F. periodonticum* – for early, mid-exponential growth and early
31 stationary phase. These data are made available in an online browser, and we use these
32 to uncover fundamental aspects of fusobacterial gene expression architecture and a suite
33 of noncoding RNAs. Developing a vector for functional analysis of fusobacterial genes, we
34 discover a conserved fusobacterial oxygen-induced small RNA, FoxI, which serves as a
35 post-transcriptional repressor of the major outer membrane porin FomA. Our findings
36 provide a crucial step towards delineating the regulatory networks enabling *F. nucleatum*
37 adaptation to different environments, which may elucidate how these bacteria colonize
38 different compartments of the human body.

39 **MAIN TEXT**

40 **INTRODUCTION**

41 Bacteria associated with cancer are of interest for diverse clinical reasons, which include
42 their potential oncogenic properties, use in diagnostics, and influence on treatment
43 outcome¹. A prominent recent example is the association of *Fusobacterium nucleatum*
44 with colorectal and breast cancers²⁻⁴. Originally observed through genomics studies of
45 colorectal cancer (CRC) samples^{3,4}, *F. nucleatum* is now established as a constituent of
46 microbial communities in human colorectal carcinomas^{5,6} and metastatic lesions⁷, where
47 it contributes to disease progression^{7,8} and resistance to chemotherapy^{9,10}. Links to
48 esophageal and pancreatic cancers have also been reported¹¹⁻¹³.

49 These phenomenological observations were underpinned by the discovery of
50 several molecular factors such as the adhesin FadA¹⁴ or the lectin Fap2¹⁵, which enable *F.*
51 *nucleatum* to interact with epithelial cells and recognize Gal-GalNAc (a sugar abundantly
52 displayed by CRC and breast cancer tissue), respectively. On the host side, the molecular
53 response of mammalian cells to *F. nucleatum* is also beginning to be better understood,
54 revealing which pathways allow the bacterium to adapt to host-imposed milieus^{2,14-21}. Yet,
55 in stark contrast with this growing interest in *F. nucleatum*, our molecular understanding
56 of the bacterium itself is lagging much behind other disease-associated species.

57 A gram-negative, non-motile, obligate anaerobic bacterium with a small genome in
58 the 2-2.5 Mb range, *F. nucleatum* is an abundant oral commensal of humans^{6,22}.
59 Possessing broad adhesion capabilities, the bacterium bridges early and late colonizers
60 in the oral plaque⁶. *F. nucleatum* belongs to the invasive branch of the phylum
61 *Fusobacteria* that evolved in an adaptive radiation, separating it from non-invasive
62 fusobacteria²³. Complete genome sequences are available for several members of the
63 *Fusobacterium* genus^{24,25}. However, some pioneering gene expression studies
64 notwithstanding^{26,27}, little remains known about the overall transcriptome structure,
65 RNA output and stress responses of *F. nucleatum*. To illustrate this, a single transcription
66 start site (TSS) has been determined in the entire phylum²⁸, and RNA-based annotations
67 of gene structure including untranslated regions (UTRs) and operons are generally
68 lacking for any fusobacterial species.

69 This paucity extends to post-transcriptional control: while *cis* and *trans* acting
70 regulatory RNAs, including small noncoding RNAs (sRNAs), have been comprehensively
71 described in many other bacteria²⁹⁻³¹, they have remained unreported in *F. nucleatum*.
72 Intriguingly, fusobacteria do not seem to encode any of the three common sRNA-
73 associated proteins, CsrA, Hfq, and ProQ³², which precludes straightforward sRNA
74 searches via RNA co-immunoprecipitation³⁰. Instead, high-resolution transcriptome maps
75 covering both coding and noncoding genomic regions will be needed for sRNA discovery
76 in fusobacteria. Importantly, sRNA genes tend to be tightly regulated, making them
77 excellent markers of the physiological state of a cell; yet, this also means that for
78 experimental sRNA discovery to be comprehensive, global RNA maps must be obtained
79 under different growth conditions³³. This global information could also help to overcome
80 the poor genetic tractability of fusobacteria. For example, there is a predicted CRISPR-Cas
81 system in *F. nucleatum*³⁴ but whether it is active and repurposable for chromosomal
82 modifications, as done in other bacteria^{35,36}, remains unknown.

83 Here, we have determined the primary transcriptomes³⁷ and noncoding RNA suites
84 of five different fusobacterial strains associated with humans: *F. nucleatum* subspecies
85 *nucleatum*, *animalis*, *polymorphum* and *vincentii* as well as *F. periodonticum* (included for
86 its repeatedly reported association with oral squamous cell carcinoma³⁸), henceforth
87 referred to as *Fnn*, *Fna*, *Fnp*, *Fnv* and *Fup* respectively. Our genome-wide annotations of
88 TSS, 5'UTRs, and operons identify the major expression units in different stages of growth.
89 We reveal a rich layer of putative noncoding regulators and amongst these identify an
90 oxygen-induced sRNA repressor of the synthesis of *F. nucleatum*'s most abundant outer
91 membrane porin FomA. To this end, we develop an expression vector that should be
92 broadly applicable to the functional analysis of fusobacterial genes, noncoding and coding
93 ones alike.

94

95 **RESULTS**

96 *The primary transcriptome of Fusobacterium nucleatum*

97 We obtained high-resolution RNA maps of the above five fusobacterial strains using the
98 dRNA-seq method^{37,39} for global annotation of 5' ends of transcripts. dRNA-seq
99 determines TSS by distinguishing primary (5'PPP) transcript ends from processed (5'P,

100 5'OH) RNA by a specific nuclease treatment. We generally analyzed RNA from three
101 different growth phases (Fig. 1a), i.e., early-exponential (E), mid-exponential (M) and
102 early stationary phase (S). Since dRNA-seq gave largely similar results for those genes
103 that are shared by the five fusobacterial strains analyzed here (Extended Data Fig. 1-4,
104 Supplementary Dataset 1), data presented hereafter refer to *Fnn* unless stated otherwise.
105 All transcriptomic data can be viewed in an online browser at <https://helmholtz->
106 [hiri.de/en/datasets/fusobacterium](https://helmholtz-hiri.de/en/datasets/fusobacterium).

107 As to benchmarking, dRNA-seq readily detected the annotated major TSS of the
108 *tnaAB* tryptophanase operon²⁸ (Fig. 1a). Using ANNOgesic¹⁰ and manual curation, we
109 assigned TSS to five different classes based on location and relative expression (Fig. 1b):
110 pTSS (primary or main TSS of a gene or operon), sTSS (secondary TSS, less expressed
111 than pTSS), iTSS (internal TSS within an open reading frame (ORF)), aTSS (antisense to a
112 gene or within 100 nt distance), and oTSS (orphan TSS, no associated gene).

113 The primary transcriptome of *Fnn* determined here comprises 930 TSS (Fig. 1b),
114 showing the common multiple associations with different TSS classes³⁹. For example, 37
115 pTSS (~5%) lie within upstream genes, thus also classifying as iTSS. While most TSS seem
116 constitutively active (Supplementary Dataset 1), we also observed many growth-phase
117 dependent TSS, as exemplified by the fructose uptake genes FN1438-FN1441 whose
118 transcription diminishes in stationary phase (Supplementary Fig. 1, Supplementary
119 Dataset 1). However, different from the frequently observed pervasive antisense
120 transcription in other bacteria⁴⁰, aTSS only make up ~13%. These aTSS were detected
121 primarily in the early or mid-exponential growth phases (Supplementary Dataset 1), as
122 exemplified by the aTSS near the start codon of *glpK* (FN1839, glycerol kinase).
123 Intriguingly, the *glpK* mRNA only accumulates in stationary phase (Supplementary
124 Dataset 2), which suggests a growth-phase dependent antisense control of glycerol
125 uptake and metabolism.

126

127 *Promoter and 5'UTR structure in F. nucleatum*

128 To initiate transcription, bacterial RNA polymerase (RNAP) associates with a sigma factor
129 (σ factor) to recognize promoter regions^{41,42}. *Fnn* encodes four σ factors: σ^{70} /RpoD,
130 σ^E /RpoE, one unclassified ECF family σ -factor, and one with similarity to the sporulation

131 SigH factor of phylogenetically distant *Clostridiales*^{43,44}. Scanning the -50 to +1 regions
132 upstream of pTSS with MEME⁴⁵ identified an extended -10 box as well as a -35 box for
133 recognition by housekeeping σ^{70} in ~93% of the pTSS (Fig. 1c). These two boxes flank an
134 AT-rich region, an arrangement known from ϵ -proteobacteria^{37,46}. Beyond that, we find
135 no other obvious promoter motifs under the growth conditions tested here. This suggests
136 that fusobacteria, in order to adapt to different environments, must control their genes
137 by additional mechanisms including post-transcriptional control by regulatory RNA
138 species.

139 The 5' UTR of mRNA is the primary region for post-transcriptional control in
140 bacteria. Using pTSS and sTSS, we define a median 5' UTR length of 36 nts, while we also
141 detect unusually long ones, e.g. the 324-nt 5'UTR of FN0328 (Fig. 1d, Supplementary
142 Dataset 3). A 5'-AGGAGG-3' motif resembling a Shine Dalgarno (SD) sequence is present
143 in three-quarters (76%) of all 5'UTRs. Leaderless mRNAs seem surprisingly rare in *Fnn*:
144 only 4 genes have a 5'UTR of <10 nt in length, and encode an integrase/recombinase, a
145 pseudouridine synthetase, a putative transcriptional regulator and a predicted drug
146 efflux pump, respectively (Supplementary Dataset 3).

147

148 *Transcription structure of virulence-associated genes*

149 Although *Fnn* lacks typical secretion systems for export of effector proteins, there is a
150 growing list of *Fnn* genes with proven roles in virulence^{23,24,47}, including genes encoding
151 Type V autotransporters^{44,48-50}. Our RNA maps not only show that these genes are
152 constitutively expressed but also provide expression context for many of them (Fig. 2a),
153 e.g., revealing monocistronic expression of adhesin FadA, which recognizes host cells and
154 triggers β -catenin signalling^{14,16,51}. By contrast, the important Gal-GalNac lectin Fap2 is
155 part of a dicistron. Likewise, the predicted FadA paralog FN1529 is co-expressed with
156 RadD (FN1526), a putative type Va autotransporter important for inter-species
157 adherence and biofilm formation^{52,53}.

158 The serine protease fusolisin (FN1426)⁵⁴ is a more complex case: the ORF is
159 monocistronic but the 3' region of this gene is independently transcribed into the FunR47
160 sRNA (Fig. 2a). Altogether, 65 out of 208 proposed virulence-associated genes⁵⁵ are
161 transcribed from a pTSS (Supplementary Dataset 4). Now having their 5'UTRs defined,

162 these genes lend themselves to investigation of potential post-transcriptional control of
163 fusobacterial virulence.

164

165 *RNA-based annotations of ORFs and operons*

166 RNA maps are a powerful tool to assign and correct diverse gene expression features
167 based on experimental data, which includes the global verification of ORF annotations in
168 fully sequenced genomes³⁷. To correct *Fnn* ORFs where necessary, we double-checked all
169 coding sequences (CDS) lacking a canonical starting codon or RBS, or with an extendable
170 ORF. These reannotations are in excellent agreement with the latest genome sequence
171 update at Fusoport²⁴ (Supplementary Dataset 5).

172 Small proteins represent an overlooked class of bacterial gene products whose
173 functional importance is just beginning to unfold⁵⁶. *Fnn* has 22 annotated small proteins
174 <50aa in length, many of which are associated with transposase genes or are ambiguous,
175 lacking an AUG start codon or RBS, respectively. Using our TSS maps, we enrich the
176 genome annotation with three previously overlooked high-confidence candidates of
177 small ORFs, naming them *fspC1* to *fspC3*. For example, we propose *fspC3* to encode a
178 conserved ~48 aa hydrophobic peptide and to be co-transcribed with an operon for
179 nucleotide metabolism and tRNA maturation/repair functions (Fig. 2b). The *fspC1* ORF
180 encodes a 41-aa peptide with a predicted transmembrane domain and lies close to the
181 gene of anti-termination factor NusB (Supplementary Fig. 2a); whereas *fspC2* lies
182 upstream of a predicted glutamate carboxypeptidase and encodes a 33-aa hydrophobic
183 peptide (Supplementary Fig. 2b). Their strong sequence conservation among
184 *Fusobacterium* species suggests that the FspC1, FspC2 and FspC3 peptides play important
185 roles in fusobacterial physiology.

186 Previous operon annotations in *Fnn* have much relied upon computational
187 inference from other bacteria⁵⁷. Our TSS-based annotation predicts a total of 428 operons
188 (Supplementary Dataset 6), which includes previously unknown polycistrons such as that
189 of phospholipase A1 type Vd autotransporter FplA (FN1704)⁵⁸ with the FN1706-FN1707
190 genes (Supplementary Fig. 7a). The longest operon predicted spans 23 genes, encoding
191 multiple ribosomal proteins and preprotein translocase SecY (Supplementary Dataset 6).
192 TSS inside primary operons predict the presence of 53 sub-operons. Of note, in ~40% (21

193 sub-operons) of such cases the iTSS uncouples the last or the last two genes from the full
194 operon (Supplementary Dataset 6). This is well illustrated with the FN1326-FN1320
195 operon, wherein gene FN1321 encoding an orphan response regulator seems to be
196 conditionally uncoupled from an upstream biosynthesis gene cluster (Supplementary Fig.
197 7b).

198

199 *Riboregulatory elements in F. nucleatum*

200 Typical 5'UTR borne *cis*-regulatory RNA elements are riboswitches and RNA
201 thermometers, which are RNA structures used by many pathogenic bacteria for location-
202 dependent post-transcriptional control of virulence genes^{59,60}. The Rfam database⁶¹ and
203 literature searches led us to annotate 12 putative riboswitches in *Fnn* (Supplementary
204 Dataset 7), three of which may sense cobalamin and thereby control genes involved in
205 uptake of vitamin B₁₂, iron, or both (FN0300, Fe²⁺/B₁₂-binding protein; FN1971, TonB-
206 dependent receptor; FN1381, putative autotransporter) (Extended Data Fig. 5). Two
207 riboswitches may sense flavin mononucleotide (FMN), one of which is associated with
208 *ribH* (FN1505) encoding the riboflavin synthase β -subunit. The remaining ones belong to
209 the families of glycine, lysine, purine, SAM, and TPP riboswitches, and are generally found
210 upstream of biosynthesis and/or metabolism genes of these ligands (Supplementary
211 Dataset 7). Ligand-responsive 5'UTRs in *F. nucleatum* further include a glucoseamine-6-
212 phosphate (GlcN6P) sensing ribozyme⁶²; as in *Bacillus subtilis*, this ribozyme may
213 feedback-control GlcN6P synthase (FN0452) levels, and thereby cell wall production.

214 Of other *cis* elements in 5'UTRs (Supplementary Dataset 7), we found an RNA leader
215 known to auto-regulate the synthesis of ribosomal protein L10^{63,64}. Additionally, a
216 putative binding site of the regulatory PyrR protein in the 5' UTR of the *pyr* operon
217 indicates transcriptional attenuation⁶⁵. By contrast, we hardly found candidates for RNA
218 thermometers. None of the five predicted candidates lie in a 5' UTR (Supplementary
219 Dataset 7). This currently leaves *F. nucleatum* without standard RNA thermometers,
220 perhaps owing to the bacterium's stable environmental temperature in the human body.

221

222 *Core noncoding RNAs and an active CRISPR-Cas system*

223 Bacteria possess several ubiquitous stable RNAs other than rRNA and tRNA, all of which
224 lacked annotation in the *Fnn* genome. Guided by Rfam database predictions, we
225 successfully probed 4.5S RNA, M1 RNA (RNase P) and tmRNA on northern blots and
226 observed constitutive expression over the course of growth (Fig. 3a). The 105-nt 4.5S
227 RNA shows the conserved apical GGAA tetraloop on which the signal recognition particle
228 (SRP) for co-translational delivery of inner membrane proteins assembles⁶⁶ (Extended
229 Data Fig. 6). As in many other bacteria⁶⁷, the ~330-nt M1 RNA is expressed independently
230 of the RNase P protein (FN0002); it is processed off a dicistronic transcript with
231 hypothetical ORF FN1315. The *Fnn* tmRNA is 363 nts long and its internal small ORF (14
232 aa) for *trans*-peptide tagging shows an interesting sequence dichotomy between oral and
233 non-oral isolates of fusobacteria (Extended Data Fig. 7). Importantly, however, its overall
234 conservation argues that tmRNA-SmpB (FN0609) protein-associated rescue of stalled
235 ribosomes on damaged mRNAs is a core process in fusobacteria.

236 6S RNA is a bacterial riboregulator shown to bind RNAP and modulate transcription
237 in *E. coli* and *B. subtilis*⁶⁸. 6S RNA genes (*ssrS*) are hard to predict for a general lack of
238 conserved primary sequence. Here, gene synteny searches combined with previous RNA
239 structure predictions by others⁶⁹ identified an *ssrS* gene between serine protease FN0508
240 and arginyl-tRNA-synthetase ArgS (FN0506), antisense to hypothetical ORF FN0507 (Fig.
241 3a-b). Several observations argue for this to be a functional 6S RNA: its overall abundance
242 and accumulation towards stationary phase; its conserved structure as a long hairpin
243 with an internal bulge mimicking a DNA open promoter complex; and our successful
244 detection of tiny (26-nt long) pRNAs whose synthesis marks 6S RNA-related RNAP
245 activity⁶⁸ (Fig. 3b-c, Extended Data Fig. 8).

246 CRISPR-Cas systems protect against unwanted foreign DNA in many bacteria. In the
247 *Fnn* genome we identified a putative type I-B system with 17 repeats (Fig. 3d), one of
248 which (repeat #11) displays a full match for the fusobacterial phage Φ Funu2 (ref. ⁷⁰). This
249 CRISPR-Cas locus must be constitutively active, given that both dRNA-seq and northern
250 blot analysis showed pre-crRNA processing into individual crRNA under all conditions
251 tested. As previously seen with type I-B systems in *Clostridium thermocellum* and
252 *Methanococcus maripaludis*⁷¹, the processing patterns are complex, exhibiting stable
253 intermediates of double or even multiple repeat-spacer pairs. Interestingly, both the Cas
254 genes and the crRNAs are upregulated in stationary phase cells, indicating a possible

255 trade-off between active anti-phage defense and growth optimization (Supplementary
256 Dataset 2). Further investigation across a greater number of strains is warranted to see
257 whether these expression and processing patterns are conserved. A preliminary analysis
258 of the four additional strains suggests that *F. periodonticum* also upregulates its CRISPR-
259 Cas defense towards the stationary phase (Supplementary Dataset 2).

260

261 *The full noncoding RNA suite*

262 To comprehensively annotate additional noncoding transcripts, we combined ANNOgesic
263 predictions¹⁰ with manual inspection of the dRNA-seq data. This yielded 43 sRNA
264 candidates from all over the genome (Fig. 4a-b), which were either transcribed from
265 independent genes in intergenic regions (IGRs) or processed off mRNAs. For
266 nomenclature, we will refer to them as FunR sRNAs until a function is assigned. Extensive
267 northern blot validation experiments using RNA samples from three growth phases
268 confirmed 24 of 43 tested candidates, ranging from 56 to 345 nts in length (Fig. 4c). Nine
269 of these validated sRNAs are expressed from stand-alone sRNA genes in IGRs
270 (Supplementary Dataset 8). Additionally, 12 ncRNAs possess promoters that exhibit the
271 same σ^{70} motif seen in mRNA genes (Supplementary Fig. 4).

272 Most of the candidate sRNAs are highly specific to *Fnn*, at least in primary sequence
273 (Fig. 4b). BLASTN analysis (75% nucleotide-identity cut-off) across 36 fusobacterial
274 species and subspecies suggests that there are some broadly-conserved fusobacterial
275 core sRNAs, e.g., FunR12 or FunR23. On the other end of the spectrum, FunR19 is found
276 in the reference strain *F. nucleatum* ATCC 25586 and only 2 additional strains. The
277 FunR19 sRNA is located in the 5' UTR of a putative reverse transcriptase gene, which is
278 reminiscent of bacterial retrons and indicates a function in specialized anti-phage
279 defence (Fig. 4c)⁷². In addition, we note intriguing similarities in genomic location to
280 sRNAs from other bacterial genera that may provide functional clues. For example, FunR7
281 being located in the 5' region of stress chaperone gene *clpB* shares its location with the
282 abundant ProQ-binding sRNA RyfD of *E. coli* and *Salmonella*^{73,74} (Fig. 4c). In *E. coli*, RyfD
283 can inhibit biofilm formation⁷⁵, which is an important physiological trait for fusobacteria
284 as well. FunR27 is a 5'UTR-derived sRNA that comprises a predicted SAM-I riboswitch
285 region of the *metK* mRNA (S-adenosylmethionine synthase). Such riboswitch-derived

286 sRNAs were proposed to act *in trans* as gene expression regulators in *Listeria*
287 *monocytogenes*⁷⁶. An interesting example of a *cis*-antisense sRNA is FunR43; it overlaps
288 with the 3' end of a SIR2-domain protein (FN1185) in a putative genomic “defence island”,
289 indicating an anti-phage function⁷⁷.

290

291 *FoxI is a conserved oxygen-induced sRNA*

292 To gain initial insight into fusobacterial sRNA functions, we selected FunR22 for further
293 analysis. As shown in Fig. 5a, FunR22 sequences are present in all *F. nucleatum* strains as
294 well as in related *F. periodonticum* and *F. hwasookii*, usually in close vicinity to the *rsmB*
295 (rRNA methyltransferase) or *trpB* (tryptophan synthase) genes. The dRNA-seq data
296 argue that FunR22 is transcribed from a stand-alone sRNA gene. Northern blotting
297 validated both, the predicted length (87 nt) and growth-phase dependent expression of
298 FunR22 (Fig. 5b). Sequence alignment of FunR22 sequences and *in silico* RNA folding
299 suggest two major sRNA regions, a 33-nt single-stranded region with a putative
300 conserved seed sequence for mRNA recognition and a long ρ -independent terminator
301 hairpin (Fig. 5c-d). Additionally, the alignment shows a highly conserved promoter region
302 that differs from the σ^{70} consensus (Fig. 5c), indicating that expression of FunR22 was
303 regulated under specific conditions. To identify such conditions, we exposed *F. nucleatum*
304 to oxidative or oxygen stress (H₂O₂ or O₂), heat shock (42°C), membrane stress (bile,
305 acidic pH, lysozyme) and iron limitation (depletion of Fe²⁺). Within this panel, we
306 observed a specific upregulation of FunR22 upon a 20-min oxygen shock, based on which
307 we renamed it FoxI for ‘Fusobacterial oxygen-induced sRNA’ (Fig. 5e).

308

309 *Plasmid pEcoFus-1 as a shuttle vector for functional analysis*

310 Functional characterization of bacterial sRNAs requires gene disruption and
311 overexpression methods as well as knowledge of sRNA-associated proteins. To advance
312 functional RNA analysis in fusobacteria, we developed a genetic system for sRNA
313 expression by building a new shuttle vector, pEcoFus (Fig. 6a), on a pRPF185 chassis⁷⁸,
314 in which the cloned (sRNA) gene of interest is expressed from the constitutive
315 fusobacterial 4.5S RNA promoter mapped above. Northern blot analysis showed that we

316 achieved stable expression of several sRNAs from this vector (Fig. 6a). Importantly, none
317 of these sRNAs was toxic, neither in the cloning vehicle *E. coli* nor in target organism, *F.*
318 *nucleatum*.

319

320 *FoxI* represses the major outer membrane protein *FomA*

321 To identify putative mRNA targets of *FoxI*, we overexpressed it in *F. nucleatum* from
322 pEcoFus (Fig. 6a). While the overexpression caused no apparent morphological changes,
323 it prevented *F. nucleatum* from reaching full cell density (Extended Data Fig. 9a), showing
324 that the cloned sRNA was physiologically active. Comparison of protein profiles revealed
325 depletion of a very abundant protein in the 35-55 kDa range in the *FoxI* expressing strain,
326 compared to empty pEcoFus (Fig. 6b). Mass spectrometry of the excised band predicted
327 this depleted protein to be the ~42 kDa outer membrane (OM) porin *FomA* (Fig. 6c and
328 Extended Data Fig. 9c-f). The OM localization of this putative *FoxI* target was fully
329 supported by cell fractionation experiments as well as western blot analysis with a *FomA*
330 antiserum (Fig. 6b).

331 Next, we used the IntaRNA algorithm⁷⁹ to predict possible base-pairing interactions
332 between *FoxI* and the *fomA* mRNA. The top prediction was an 8-bp RNA helix with a
333 bulged A, sequestering the RBS of this target and so repressing translation initiation of
334 the *fomA* mRNA (Fig. 6d). Most importantly, this interaction would fully engage a
335 conserved region of the *fomA* mRNA (Fig. 6e) and one of the two candidate seed regions
336 in *FoxI*, i.e. the conserved cytidine-rich stretch upstream of the long 3' hairpin (Fig. 5c-d).
337 Indeed, mutation of three consecutive cytidines to adenines (sRNA variant *FoxI*-3C)
338 abrogated both, the growth phenotype and the downregulation of *FomA* (Figs. 6b-c and
339 Extended Data Fig. 9a). Expression of the sRNA itself, however, was largely unaffected by
340 this mutation (Extended Data Fig. 9b). Thus, the almost complete depletion of one of the
341 most abundant *Fnn* proteins by the *FoxI* sRNA is very likely to occur on the post-
342 transcriptional level by a mechanism of translational repression.

343

344 **DISCUSSION**

345 The phylum Fusobacteria, despite its importance for human and veterinary medicine, is
346 understudied with respect to molecular mechanisms of gene expression and RNA biology.
347 Our global RNA maps obtained for five fusobacterial strains provide an important
348 resource in the quest to understand how gene regulation enables this group of microbes
349 to dwell and proliferate in diverse animals⁶. In addition, while high-throughput screening
350 for fusobacterial gene function is in its infancy^{80,81}, our single-nucleotide expression maps
351 will be invaluable for scoring effects of transposon insertions outside reading frames. Our
352 study increases by a factor of thousand the number of mapped 5' ends, effectively
353 assigning a primary TSS or polycistronic transcription to the majority of *F. nucleatum*
354 genes. Specifically, we have assigned TSS to 706 genes or operons, which include the two
355 major virulence factors FadA and Fap2 and ~200 other putative virulence factors⁵⁵ (Figs.
356 1b and 2a, Supplementary Dataset 1). Their observed growth-independent expression
357 starkly contrasts with the common condition-dependent induction of virulence genes in
358 many other human pathogens. This supports *F. nucleatum*'s role as an opportunistic
359 pathogen and generalist⁸², thus in part explaining why the bacterium can colonize
360 additional sites in the human body.

361 Regarding general transcription signals, our analysis of different growth stages
362 shows that the majority of fusobacterial promoters possess an extended -10 box; a -35
363 box is less prevalent in *Fnp* and *Fnv*. Despite these differences, our results indicate a
364 shared recognition sequence for the fusobacterial housekeeping σ^{70} factor. Intriguingly,
365 the fusobacterial promoters differ from those of closely related species (e.g., *Bacteroides*
366 *fragilis*⁸³, *B. thetaiotaomicron*⁸⁴ or *Porphyromonas gingivalis*⁸⁵), and seem more similar
367 to promoters of proteobacteria^{37,41,46} or Firmicutes⁸⁶.

368 We not only correct the *in silico* annotation for ~22% of all genes of *F. nucleatum*,
369 but also add hundreds of functional elements. In addition to three previously overlooked
370 conserved small ORFs, we provide evidence for a rich layer of noncoding RNAs of diverse
371 origin including a dozen sRNAs from "empty" intergenic regions. Except for four
372 ubiquitous RNAs (6S RNA, 4.5S RNA, tmRNA, M1 of RNase P), the fusobacterial sRNAs
373 seem unique, showing no obvious sequence homology outside this phylum. Yet, our
374 discovery of FoxI as a repressor of the major porin FomA establishes proof-of-principle
375 that fusobacteria share with many other bacteria the use of sRNAs to regulate envelope
376 composition²⁹. Mechanistically, we consider it likely that *in vivo*, stable formation of the

377 predicted 8-bp FoxI-*fomA* RNA duplex is mediated by an RNA-binding protein (RBP).
378 Since fusobacteria lack CsrA, Hfq, and ProQ^{87,88}, the use of FoxI as an RNA bait in
379 experimental RBP discovery^{30,74} promises to expand the currently known set of sRNA-
380 related RBPs. Candidates include the KhpA/B proteins, which have been predicted to
381 associate with sRNAs in gram-positive species⁸⁹⁻⁹¹.

382 Work in other bacteria has shown that conserved sRNAs are often the most
383 stringently regulated genes within a given regulon⁹²⁻⁹⁵. While the reported colonization
384 of different body sites^{2-4,96-101} implies that *F. nucleatum* possesses multiple environmental
385 sensing and stress response pathways, the responsible TFs are unknown. Here, we
386 observe strong and selective upregulation of the FoxI sRNA after oxygen exposure, paired
387 with exceptional sequence conservation of the *foxI* promoter, indicating the presence of
388 key elements for its oxygen-dependent activation (or derepression). These observations
389 provide invaluable starting points to find a TF that enables *F. nucleatum* to respond to
390 elevated oxygen levels. Physiologically, the FoxI-mediated repression of FomA synthesis
391 when *F. nucleatum* senses an oxygen-rich environment, i.e., after leaving its stable niches
392 in oral biofilms or cancer tissue, may protect from the host's immune system, for FomA
393 is known to be recognized by both adapted and innate immune pathways¹⁰².

394 In conclusion, high-resolution RNA maps are essential prerequisites for the study
395 of host-pathogen interactions by advanced transcriptomics methods such as dual RNA-
396 seq¹⁰³ or bacterial single-cell RNA-seq^{104,105}, in particular, when trying to track *F.*
397 *nucleatum* gene activity in cancer tissue. Improving the poor genetic tractability of this
398 organism, our new shuttle vector (Fig. 6a) should help to accelerate the discovery of gene
399 function in niche adaptation and survival. Furthermore, this expression system may
400 facilitate genome-wide antisense knockdown of chromosomal genes, as pioneered in
401 *Staphylococcus aureus* 19 years ago¹⁰⁶. Alternatively, it may be used to repurpose
402 CRISPR-Cas locus of *F. nucleatum*, which is here shown to be functional (Fig. 3d), for
403 intrinsic gene regulation. All in all, the RNA-centric approach taken here opens up new
404 avenues for molecular microbiology excursions into an understudied phylum of great
405 medical importance.

406

407 **METHODS**

408 *Bacterial strains and growth conditions*

409 All oligonucleotides, plasmids or strains used in this study can be found in Supplementary
410 Dataset 9. This study utilized four different subspecies of *Fusobacterium nucleatum*:
411 *Fusobacterium nucleatum* subsp. *nucleatum* (ATCC 25586 and ATCC 23726), subsp.
412 *polymorphum* (ATCC 10953), subsp. *vincentii* 3_1_36A2 and subsp. *animalis* 7_1, as well
413 as a strain of *Fusobacterium periodonticum*. ATCC 25586 and ATCC 10953 were obtained
414 from the German Collection of Microorganisms and Cell Culture (DSMZ, Germany) and
415 ATCC 23726 was obtained from the American Type Culture Collection (ATCC, USA). The
416 *Fnv*, *Fna* and *Fup* strains were a kind gift from Emma Allen-Vercoe (University of Guelph,
417 Canada). *F. nucleatum* was routinely grown at 37 °C in 80:10:10 (N₂:H₂:CO₂) on Brain-
418 Heart-Infusion (BHI) 2% agar plates supplemented with 1% (w/vol) yeast-extract, 1%
419 (w/vol) glucose, 5 µg/ml hemin and 1% (vol/vol) FBS (BHI-C). Liquid cultures for all
420 experiments were grown in Columbia Broth medium without agitation (see below). Pre-
421 cultures were prepared 24h prior to inoculating working cultures at a 1:50 dilution.
422 When using *F. nucleatum* subsp. *nucleatum* ATCC 23726 carrying a plasmid, agar plates
423 were supplemented with 5 µg/ml Thiamphenicol and liquid cultures contained 2.5 µg/ml
424 of the antibiotic.

425

426 *Sample collection for dRNA-seq analysis and RNA-extraction*

427 Samples for dRNA-seq analysis were collected from bacterial cultures corresponding to
428 the early logarithmic, mid-logarithmic and early stationary growth phase. Three
429 biological replicates were collected for each time point. Samples were fixed by the
430 addition of STOP Mix [95% (vol/vol) EtOH, 5% (vol/vol)] phenol prior to snap-freezing
431 in liquid nitrogen. All samples were subsequently stored at -80 °C until RNA extraction.
432 RNA extraction was performed as previously reported³⁷. In short, frozen bacterial
433 cultures were thawed on ice, centrifuged and cell pellets were resuspended in lysis
434 solution (600 µl of 0.5 mg/ml lysozyme in TE buffer (pH 8.0) with 60 µl 10% SDS).
435 Bacterial cells were lysed by placing the samples for 2 minutes at 65°C in a water bath
436 and the reaction stopped by addition of 65 µl of 3M Sodium acetate (pH 5.2). Total RNA
437 was extracted from the lysates using the hot phenol method¹⁰⁷.

438

439 *Generation and sequencing of cDNA libraries for dRNA-seq and RNA-seq*

440 cDNA libraries for dRNA-seq were generated by Vertis Biotechnology AG, Munich,
441 Germany. This was performed as described in *Berezikov et al. (2010)*¹⁰⁸ while omitting
442 the RNA size-fractionation step prior to cDNA-synthesis. To summarize, two libraries
443 were created for each total RNA sample for which one included all transcripts (TEX-) and
444 the second one was enriched for primary transcripts by treatment with terminator
445 exonuclease (TEX+). This was followed by addition of a poly(A)-tail to equal amounts of
446 RNA samples using a poly(A) polymerase. Next, the 5'triphosphate residues were
447 removed with tobacco acid pyrophosphatase (TAP) prior to ligation of 5'RNA adapter.
448 This was used for the generation of first-strand cDNA using oligo(dT)-adapter primer and
449 MMLV transcriptase. The cDNA concentration was further increased to 20-30 ng/ μ l
450 through PCR-amplification utilizing a high-fidelity DNA-polymerase. Library specific
451 barcodes were included for the 5'sequencing adapters to allow for multiplexing. cDNA
452 libraries for the untreated samples were performed in a similar fashion except that the
453 TEX treatment was omitted, the final cDNA concentration were 10-20ng/ μ l and barcode
454 sequences were included in the 5' and 3' TrueSeq sequencing adapters. The different
455 cDNA libraries were pooled in approximately equimolar amounts before being
456 sequenced on an Illumina NextSeq 500 system (75bp single-end read length). The cDNA
457 libraries were sequenced with Vertis Biotechnology AG, Munich, Germany (for *F. n. subsp.*
458 *nucleatum* and *polymorphum*) or by the Core Unit SysMed (University Würzburg) (for *F.*
459 *n. subsp. animalis, vincentii* and *F. periodonticum*)

460

461 *Read mapping of dRNA-seq data*

462 The RAW data is available at GEO under accession GSE161360. Adapters clipping and
463 quality trimming of the Illumina reads in FASTQ format was performed using the
464 `fastq_quality_trimmer` function of the FASTX toolkit version 0.10.1
465 (http://hannonlab.cshl.edu/fastx_toolkit/). The READemption 0.4.3 tool was used to
466 perform the following steps with the usage of its subcommands "create", "align" and
467 "coverage"¹⁰⁹: The poly(A)-tail sequences were computationally removed prior to size-
468 filtering step which excluded all sequences <12 nt. The following reference genomes for
469 each isolate were downloaded from the NCBI ftp server and used for mapping via

470 Segemehl version 0.2.0 (ref. ¹¹⁰): *F. nucleatum* subsp. *nucleatum* (NC_003454.1), *F.*
471 *nucleatum* subsp. *polymorphum* (NZ_CM000440.1), *F. nucleatum* subsp. *animalis*
472 (NZ_CP007062.1), *F. nucleatum* subsp. *vincentii* (NC_022196.1), *F. periodonticum*
473 (NZ_CP028108.1).

474

475 *Prediction of TSS, transcripts, UTRs, operons, sORFs, sRNAs, CRISPR locus, regulatory RNA-*
476 *elements and terminators*

477 For the following predictions, the ANNOgesic tool was used¹⁰: All parameters were kept
478 at the default setting, if not otherwise specified. TSS were predicted using the default
479 setting of ANNOgesic, which further categorizes the TSS into 5 different classes: primary,
480 secondary, internal, antisense and orphan TSS. For this, all parameters had to be met
481 within all replicates of each condition in order to be annotated as a TSS. Additionally,
482 predicted secondary TSSs were excluded if a primary TSS was predicted to be <7 nt away.
483 The TSS prediction was further improved by manual curation. The annotation of UTRs
484 was conducted by adjusting the default settings to allow for a maximum length of 300 nt
485 and by extending 5'UTRs up to 25 nt to be connected with detected transcripts. All sRNAs
486 were predicted through the input of detected promoter sequences (see below) while
487 further allowing for the detection of 5'UTR-derived sRNAs. Additionally, ANNOgesic takes
488 TSS, coverage and the presence of terminators into account when predicting the length
489 of sRNA candidates. For predictions of transcripts, operon structures, CRISPR locus and
490 regulatory RNA-elements the default settings of ANNOgesic were used. Rho-independent
491 terminator prediction was carried out using ANNOgesic which combines two heuristic
492 prediction algorithms: TransTermHP¹¹¹ analysis and a detection of sharp coverage
493 decreases around the predicted terminator sequence.

494

495 *Promoter, Shine-Dalgarno and prophage sequence detection*

496 To detect putative promoter motifs, 50nt upstream of each detected TSS including the
497 TSS position were extracted using BEDtools¹¹² and further analysed with MEME version
498 4.12.0⁴⁵. The same procedure was performed for all genes lacking a primary TSS. For this,
499 100 nt long sequences upstream of the start codon were extracted in order to account for

500 unaccounted 5'UTRs. To identify SD sequences, all 5'UTR sequences were extracted (see
501 above) and used as input for MEME analysis.

502

503 *Northern blot analysis*

504 For northern blot analysis, 3-10 µg of DNase I-treated total RNA from three biological
505 replicates for each time point or strain was separated on a 6% polyacrylamide (PAA) gel
506 containing 7 M urea. After transfer of the RNA to Hybond-XL membranes, hybridization
507 took place overnight at 42 °C with $\gamma^{32}\text{P}$ -ATP end-labelled deoxyribonucleotide probes. A
508 Typhoon FLA 7000 phosphorimager (GE Healthcare) was used for signal visualization.

509

510 *Re-annotation of coding sequences*

511 All annotated CDS were checked for the presence of an AUG start codon. Additionally, 20
512 nt upstream of the start codon were extracted to analyse if a Shine Dalgarno sequence
513 was present. In the absence of either, the ORFs were manually inspected. In the case of a
514 missing AUG start codon, the sequences were surveyed for an in-frame start codon up- or
515 downstream of the annotated start. A similar analysis was conducted in case of an absent
516 Shine Dalgarno sequence. CDS for which the corrected start was supported by both the
517 presence of a start codon (AUG, GUG or UUG) and a Shine Dalgarno sequence as well as
518 by sequence conservation in other *F. n. subspp. nucleatum* strains were included for re-
519 annotation.

520

521 *Construction of shuttle vector pEcoFus*

522 The *E. coli* – *C. difficile* shuttle vector pRPF185⁷⁸ was used as a backbone. In the first step,
523 the backbone was opened by inverse PCR using primers JVO-17251/17252 to remove
524 *repA* and *orfB* while introducing PvuI and NotI restriction sites. The origin of replication
525 for *F. nucleatum* was amplified from pORI92 (a gift from G. Bachrach) using primers JVO-
526 17207/17248 to introduce PvuI and NotI restriction sites, cut and ligated with the
527 backbone resulting in pFP14. Next, pFP14 was digested with KpnI and BamHI before
528 being assembled together with an amplified fragment of the 100nt promoter region of

529 the 4.5S RNA using the NEBuilder® Hifi Assembly Cloning kit and transformed into *E. coli*
530 topF'. This resulted in the vector pEcoFus for constitutive overexpression for any gene of
531 interest.

532

533 *Construction of sRNA expression plasmids*

534 Overexpression plasmids for different sRNAs were assembled using Gibson Assembly
535 protocol. Full-length sRNA sequences for FoxI (JVO-17259/17302), FunR47 (JVO-
536 17306/17307), FunR7 (JVO-17543/17544), FunR7+extended 3'end (JVO-17543/17545),
537 FunR12 (JVO-17549/17550) and FunR16 (JVO-17558/17559) were amplified from
538 chromosomal DNA of *F. nucleatum subsp. nucleatum* ATCC 25586 and assembled with
539 BamHI-digested pEcoFus using NEBuilder® Hifi Assembly Cloning kit and transformed
540 into *E. coli* topF'. Correct sequences were verified by sequencing.

541

542 *Electroporation of F. nucleatum subsp. nucleatum ATCC 23726*

543 Electro-competent cells of the genetically tractable *F. nucleatum subsp. nucleatum* ATCC
544 23726 were generated in a similar fashion as described in *Haake et al. (2000)*¹¹³. In short,
545 cells were harvested from mid-exponential phase at 4000xg for 10min at 4°C.
546 Subsequently the cells were washed in ice-cold and pre-reduced 10% (V/V) glycerol
547 solution for a total of 5 washes. Finally, the cells were resuspended to 60 OD/ml in 10%
548 glycerol solution, aliquoted and stored at -80°C until use. 80µl of competent cells were
549 transformed with 5µg of dialyzed plasmid (2.0 kV, 1 mm gap) and recovered in Columbia
550 broth containing 1 mM MgCl₂ for 2h before plating the bacteria on BHI-C plates containing
551 5 µg/ml Thiamphenicol. This routinely yielded >10 CFU/µg plasmid DNA. Transformants
552 were re-streaked onto fresh BHI-C before verification of carrying the correct insert and
553 preparation of glycerol stocks or downstream analyses.

554

555 *Stress exposure of F. nucleatum*

556 *Fnn* was grown to mid-exponential phase before being exposed to different stress
557 conditions for 20min. The following were conducted inside the anaerobic chamber: H₂O₂

558 (400 μ M; AppliChem), bile (0.05 % (w/v); Sigma Aldrich (70168)), iron depletion (300 μ M;
559 2,2-Bipyridyl; Sigma Aldrich (D216305-10G)) and lysozyme (50 μ g/ml; Roth (8259.2)).
560 All treated cultures and the untreated control were kept in the incubator at 37°C for the
561 duration of the treatment. For acidic pH treatment the bacteria were harvested (37°C;
562 5min at 4000xg) and resuspended in pH-adjusted (pH 5.5 or pH 7 for the control) pre-
563 warmed and reduced media. Similarly, for the O₂ shock, the samples were spread onto
564 petri dishes and incubated at 37°C under atmospheric conditions. The heat shock was
565 conducted at 42.5°C in a water bath outside the chamber. Prior to removing samples from
566 the chamber, the falcons were wrapped with parafilm to avoid oxygen exposure. At the
567 end of each treatment, cells were fixed in STOP mix and RNA was isolated as described
568 above.

569

570 *Subcellular fractionation*

571 Subcellular fractionation was performed as described by *Knoke et al. (2020)*¹¹⁴ for two
572 biological replicates. In short, 50 OD₆₀₀ units were harvested from mid-exponential phase
573 cultures at 4000xg for 10min at 4°C. The cell pellet was resuspended in lysis buffer (10
574 mM Tris-HCl (pH 7.5), 0.2 mM PMSF, 1 mM MgCl₂) and total protein samples were
575 collected. The cells were lysed via sonication and centrifuged at 4000xg for 10min at 4°C.
576 A lysate sample was collected prior to performing another centrifugation step at
577 15,000xg for 1h at 4°C. Samples for the cytosolic fraction were collected and the pellet
578 was incubated with 0.5 % N-lauroylsarcosine in lysis buffer overnight at 4°C to separate
579 inner and outer membrane. Another high-speed centrifugation step was performed
580 (100,000xg for 2h at 4°C) collecting the inner membrane fraction and dissolving the outer
581 membrane fraction in lysis buffer containing 0.5% Triton X-100. For denaturing SDS-page
582 analysis, 0.1 OD₆₀₀ were loaded for total cell lysate and the cytosolic fraction while 1 OD₆₀₀
583 was loaded for both inner and outer membrane fraction. For western blot analysis of
584 FomA, a polyclonal antibody was generated in rabbits against a synthetic peptide derived
585 from FomA (amino acid sequence: KKFATYNKGDKKSQF). Peptide synthesis, validation
586 via ELISA and subsequent antigen-purification was performed by Eurogentec (Belgium).
587 Afterwards an unstained gel was transferred to a PVDF membrane (GE Healthcare Life

588 Sciences) and incubated with anti-FomA antibody before being detected using an anti-
589 rabbit secondary antibody (Thermo Fisher Scientific, cat# 31460).

590

591 *nanoLC-MS/MS analysis of protein samples*

592 Quantification of FomA from *F. nucleatum* samples was conducted similarly as described
593 in Hör *et al.* (2020)⁹¹. Denatured samples for total protein (empty vector control, FoxI or
594 FoxI-3C overexpression) or the outer membrane fraction (empty vector control) were
595 separated on a denaturing 15% SDS-gel and for each sample the region of interest was
596 excised from the gels for two replicates (Fig. 6b). The samples were destained in 100 mM
597 ammonium bicarbonate containing 30% acetonitrile and shrunk in 100% acetonitrile
598 prior to trypsin digestion (0.1 µg in 100 mM ammonium bicarbonate, overnight at 37°C).
599 The samples were then dissolved in 5% formic acid for subsequent nanoLC-MS/MS
600 analysis. For nanoLC-MS/MS analysis an Orbitrap Fusion (Thermo Fisher Scientific)
601 combined with a PicoView Ion source (New Objective) and an Easy-nLC 1000 (Thermo
602 Fisher Scientific) was used. The dissolved samples were loaded on PicoFrit capillary
603 columns (30cm x 150 µM ID, New Objective) packed with ReproSil-Pur 120 C18-AQ (1.9
604 µM, Dr. Maisch) and separated using a 140-min linear gradient (3-30% acetonitrile, 0.1%
605 formic acid) at a flow rate of 500nl/min. Both MS (60,000 scans; target value for AGC:
606 2×10^5) and MS/MS (7,500 scans; target value for AGC: 5×10^4) analysis were conducted
607 using the Orbitrap with the HCD fragmentation set to 35% normalized collision energy.
608 A fixed cycle time of 3 s was used for the Top Speed data-dependent MS/MS method while
609 a further exclusion of 1 repeat count per minute was applied. Precursor selection was
610 conducted at a minimum threshold of 50,000 while excluding single charged ones.
611 Internal calibration with Easy-IC was used to improve mass-to-charge ratio assignment.
612 Subsequent analysis of the data was conducted using MaxQuant (version 1.5.7.4)¹¹⁵ with
613 integrated Andromeda comparing it against the Uniprot database for *F. nucleatum subsp.*
614 *nucleatum* ATCC 25586 (FUSNN).

615 *Data visualization*

616 Coverage plots were generated with the R packages Gviz (v1.32.0). Gene cartoons were
617 generated using the R packages gggenes (v0.4.0). The web browser was build using
618 jbrowse (v1.16.2).

619 *Statistics and Reproducibility*

620 The dRNA-seq was performed in biological triplicates. Northern blot analysis for growth
621 condition was performed in biological triplicates and for the sRNA overexpression in
622 biological duplicates. The subcellular fractionation was conducted for two biological
623 replicates. The samples size was determined based upon experience with previous
624 studies.

625 **Data availability**

626 RNA-seq data can be accessed at NCBI Gene Expression Omnibus
627 (<https://www.ncbi.nlm.nih.gov/geo/>) under the accession number GSE161360.

628 MS data can be accessed at the Proteomics Identification Database PRIDE
629 (<https://www.ebi.ac.uk/pride>) under the accession number PXD022474.

630 The RFAM database can accessed at <http://rfam.xfam.org/>.

631 The Uniprot database can be accessed at
632 <https://www.uniprot.org/uniprot/?query=taxonomy:190304>.

633 **ACKNOWLEDGEMENT**

634 We are grateful to Youssef el Mouali Benomar, Jens Hör, Daniel Ryan and Gilad Bachrach
635 for fruitful discussions; Elisa Venturini for support with the subcellular fractionation;
636 Gilad Bachrach (The Hebrew University of Jerusalem, Israel) for providing pORI92;
637 Emma Allen-Vercoe (University Guelph, Canada) for providing *Fusobacterium* strains;
638 Laura Jenniches for help with launching the web browser. We thank Stephanie Lamer and
639 Andreas Schlosser for mass spectrometry analysis. We thank the Vogel Stiftung Dr.
640 Eckernkamp for supporting FP with a Dr. Eckernkamp Fellowship. This work was funded
641 by a DFG Gottfried Wilhelm Leibniz Award to JV (DFG Vo875-18). The funders had no role
642 in study design, data collection and analysis, decision to publish or preparation of the
643 manuscript.

644

645 **REFERENCES**

- 646 1 Dzutsev, A. *et al.* Microbes and Cancer. *Annual review of immunology* **35**, 199-228,
647 doi:10.1146/annurev-immunol-051116-052133 (2017).
- 648 2 Parhi, L. *et al.* Breast cancer colonization by *Fusobacterium nucleatum* accelerates
649 tumor growth and metastatic progression. *Nat Commun* **11**, 3259, doi:10.1038/s41467-
650 020-16967-2 (2020).
- 651 3 Kostic, A. D. *et al.* Genomic analysis identifies association of *Fusobacterium* with
652 colorectal carcinoma. *Genome Res* **22**, 292-298, doi:10.1101/gr.126573.111 (2012).
- 653 4 Castellarin, M. *et al.* *Fusobacterium nucleatum* infection is prevalent in human colorectal
654 carcinoma. *Genome Res* **22**, 299-306, doi:10.1101/gr.126516.111 (2012).
- 655 5 Hussan, H., Clinton, S. K., Roberts, K. & Bailey, M. T. *Fusobacterium*'s link to colorectal
656 neoplasia sequenced: A systematic review and future insights. *World journal of*
657 *gastroenterology* **23**, 8626-8650, doi:10.3748/wjg.v23.i48.8626 (2017).
- 658 6 Brennan, C. A. & Garrett, W. S. *Fusobacterium nucleatum* - symbiont, opportunist and
659 oncobacterium. *Nature reviews. Microbiology* **17**, 156-166, doi:10.1038/s41579-018-
660 0129-6 (2019).
- 661 7 Bullman, S. *et al.* Analysis of *Fusobacterium* persistence and antibiotic response in
662 colorectal cancer. *Science (New York, N.Y.)* **358**, 1443-1448,
663 doi:10.1126/science.aal5240 (2017).
- 664 8 Amitay, E. L. *et al.* *Fusobacterium* and colorectal cancer: causal factor or passenger?
665 Results from a large colorectal cancer screening study. *Carcinogenesis* **38**, 781-788,
666 doi:10.1093/carcin/bgx053 (2017).
- 667 9 Yu, T. *et al.* *Fusobacterium nucleatum* Promotes Chemoresistance to Colorectal Cancer
668 by Modulating Autophagy. *Cell* **170**, 548-563.e516, doi:10.1016/j.cell.2017.07.008
669 (2017).
- 670 10 Yu, S. H., Vogel, J. & Forstner, K. U. ANNOgesic: a Swiss army knife for the RNA-seq based
671 annotation of bacterial/archaeal genomes. *GigaScience* **7**,
672 doi:10.1093/gigascience/giy096 (2018).
- 673 11 Gaiser, R. A. *et al.* Enrichment of oral microbiota in early cystic precursors to invasive
674 pancreatic cancer. *Gut* **68**, 2186-2194, doi:10.1136/gutjnl-2018-317458 (2019).
- 675 12 Yamamura, K. *et al.* *Fusobacterium nucleatum* in gastroenterological cancer: Evaluation
676 of measurement methods using quantitative polymerase chain reaction and a literature
677 review. *Oncology letters* **14**, 6373-6378, doi:10.3892/ol.2017.7001 (2017).
- 678 13 Yamamura, K. *et al.* Human Microbiome *Fusobacterium Nucleatum* in Esophageal Cancer
679 Tissue Is Associated with Prognosis. *Clinical cancer research : an official journal of the*
680 *American Association for Cancer Research* **22**, 5574-5581, doi:10.1158/1078-0432.Ccr-
681 16-1786 (2016).
- 682 14 Rubinstein, M. R. *et al.* *Fusobacterium nucleatum* promotes colorectal carcinogenesis by
683 modulating E-cadherin/beta-catenin signaling via its FadA adhesin. *Cell Host Microbe* **14**,
684 195-206, doi:10.1016/j.chom.2013.07.012 (2013).

- 685 15 Abed, J. *et al.* Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma
686 Enrichment by Binding to Tumor-Expressed Gal-GalNAc. *Cell Host Microbe* **20**, 215-225,
687 doi:10.1016/j.chom.2016.07.006 (2016).
- 688 16 Han, Y. W. *et al.* Identification and characterization of a novel adhesin unique to oral
689 fusobacteria. *J Bacteriol* **187**, 5330-5340, doi:10.1128/JB.187.15.5330-5340.2005
690 (2005).
- 691 17 Holt, R. A. & Cochrane, K. Tumor Potentiating Mechanisms of Fusobacterium nucleatum,
692 A Multifaceted Microbe. *Gastroenterology* **152**, 694-696,
693 doi:10.1053/j.gastro.2017.01.024 (2017).
- 694 18 Kaplan, C. W. *et al.* Fusobacterium nucleatum outer membrane proteins Fap2 and RadD
695 induce cell death in human lymphocytes. *Infect Immun* **78**, 4773-4778,
696 doi:10.1128/IAI.00567-10 (2010).
- 697 19 Gur, C. *et al.* Binding of the Fap2 protein of Fusobacterium nucleatum to human
698 inhibitory receptor TIGIT protects tumors from immune cell attack. *Immunity* **42**, 344-
699 355, doi:10.1016/j.immuni.2015.01.010 (2015).
- 700 20 Cochrane, K., Robinson, A. V., Holt, R. A. & Allen-Vercoe, E. A survey of Fusobacterium
701 nucleatum genes modulated by host cell infection. *Microb Genom* **6**,
702 doi:10.1099/mgen.0.000300 (2020).
- 703 21 Abed, J. *et al.* Colon Cancer-Associated Fusobacterium nucleatum May Originate From
704 the Oral Cavity and Reach Colon Tumors via the Circulatory System. *Front Cell Infect*
705 *Microbiol* **10**, 400, doi:10.3389/fcimb.2020.00400 (2020).
- 706 22 Han, Y. W. Fusobacterium nucleatum: a commensal-turned pathogen. *Current opinion in*
707 *microbiology* **23**, 141-147, doi:10.1016/j.mib.2014.11.013 (2015).
- 708 23 Manson McGuire, A. *et al.* Evolution of invasion in a diverse set of Fusobacterium
709 species. *MBio* **5**, e01864, doi:10.1128/mBio.01864-14 (2014).
- 710 24 Sanders, B. E., Umana, A., Lemkul, J. A. & Slade, D. J. FusoPortal: an Interactive Repository
711 of Hybrid MinION-Sequenced Fusobacterium Genomes Improves Gene Identification
712 and Characterization. *mSphere* **3**, doi:10.1128/mSphere.00228-18 (2018).
- 713 25 Kook, J. K. *et al.* Genome-Based Reclassification of Fusobacterium nucleatum Subspecies
714 at the Species Level. *Curr Microbiol* **74**, 1137-1147, doi:10.1007/s00284-017-1296-9
715 (2017).
- 716 26 Merritt, J., Niu, G., Okinaga, T. & Qi, F. Autoaggregation response of Fusobacterium
717 nucleatum. *Appl Environ Microbiol* **75**, 7725-7733, doi:10.1128/AEM.00916-09 (2009).
- 718 27 Mutha, N. V. R. *et al.* Transcriptional responses of Streptococcus gordonii and
719 Fusobacterium nucleatum to coaggregation. *Mol Oral Microbiol* **33**, 450-464,
720 doi:10.1111/omi.12248 (2018).
- 721 28 Sasaki-Imamura, T., Yano, A. & Yoshida, Y. Production of indole from L-tryptophan and
722 effects of these compounds on biofilm formation by Fusobacterium nucleatum ATCC
723 25586. *Appl Environ Microbiol* **76**, 4260-4268, doi:10.1128/aem.00166-10 (2010).

- 724 29 Wagner, E. G. & Romby, P. Small RNAs in bacteria and archaea: who they are, what they
725 do, and how they do it. *Advances in genetics* **90**, 133-208,
726 doi:10.1016/bs.adgen.2015.05.001 (2015).
- 727 30 Hör, J., Gorski, S. A. & Vogel, J. Bacterial RNA Biology on a Genome Scale. *Mol Cell* **70**, 785-
728 799, doi:10.1016/j.molcel.2017.12.023 (2018).
- 729 31 Hör, J., Matera, G., Vogel, J., Gottesman, S. & Storz, G. Trans-Acting Small RNAs and Their
730 Effects on Gene Expression in Escherichia coli and Salmonella enterica. *EcoSal Plus* **9**,
731 doi:10.1128/ecosalplus.ESP-0030-2019 (2020).
- 732 32 Babitzke, P., Lai, Y. J., Renda, A. J. & Romeo, T. Posttranscription Initiation Control of
733 Gene Expression Mediated by Bacterial RNA-Binding Proteins. *Annu Rev Microbiol* **73**,
734 43-67, doi:10.1146/annurev-micro-020518-115907 (2019).
- 735 33 Barquist, L. & Vogel, J. Accelerating Discovery and Functional Analysis of Small RNAs
736 with New Technologies. *Annual review of genetics* **49**, 367-394, doi:10.1146/annurev-
737 genet-112414-054804 (2015).
- 738 34 Ang, M. Y. *et al.* Comparative Genome Analysis of Fusobacterium nucleatum. *Genome Biol*
739 *Evol* **8**, 2928-2938, doi:10.1093/gbe/evw199 (2016).
- 740 35 Pyne, M. E., Bruder, M. R., Moo-Young, M., Chung, D. A. & Chou, C. P. Harnessing
741 heterologous and endogenous CRISPR-Cas machineries for efficient markerless genome
742 editing in Clostridium. *Scientific reports* **6**, 25666, doi:10.1038/srep25666 (2016).
- 743 36 Li, Y. *et al.* Harnessing Type I and Type III CRISPR-Cas systems for genome editing.
744 *Nucleic acids research* **44**, e34, doi:10.1093/nar/gkv1044 (2016).
- 745 37 Sharma, C. M. *et al.* The primary transcriptome of the major human pathogen
746 Helicobacter pylori. *Nature* **464**, 250-255, doi:10.1038/nature08756 (2010).
- 747 38 Minarovits, J. Anaerobic bacterial communities associated with oral carcinoma:
748 Intratumoral, surface-biofilm and salivary microbiota. *Anaerobe* **68**, 102300,
749 doi:10.1016/j.anaerobe.2020.102300 (2021).
- 750 39 Sharma, C. M. & Vogel, J. Differential RNA-seq: the approach behind and the biological
751 insight gained. *Current opinion in microbiology* **19**, 97-105,
752 doi:10.1016/j.mib.2014.06.010 (2014).
- 753 40 Georg, J. & Hess, W. R. Widespread Antisense Transcription in Prokaryotes. *Microbiology*
754 *spectrum* **6**, doi:10.1128/microbiolspec.RWR-0029-2018 (2018).
- 755 41 Feklistov, A., Sharon, B. D., Darst, S. A. & Gross, C. A. Bacterial sigma factors: a historical,
756 structural, and genomic perspective. *Annu Rev Microbiol* **68**, 357-376,
757 doi:10.1146/annurev-micro-092412-155737 (2014).
- 758 42 Browning, D. F. & Busby, S. J. W. The regulation of bacterial transcription initiation.
759 *Nature Reviews Microbiology* **2**, 57, doi:10.1038/nrmicro787 (2004).
- 760 43 Karpathy, S. E. *et al.* Genome sequence of Fusobacterium nucleatum subspecies
761 polymorphum - a genetically tractable fusobacterium. *PLoS One* **2**, e659,
762 doi:10.1371/journal.pone.0000659 (2007).

- 763 44 Kapatral, V. *et al.* Genome Sequence and Analysis of the Oral Bacterium *Fusobacterium*
764 *nucleatum* Strain ATCC 25586. *Journal of Bacteriology* **184**, 2005-2018,
765 doi:10.1128/jb.184.7.2005-2018.2002 (2002).
- 766 45 Bailey, T. L., Johnson, J., Grant, C. E. & Noble, W. S. The MEME Suite. *Nucleic acids research*
767 **43**, W39-49, doi:10.1093/nar/gkv416 (2015).
- 768 46 Dugar, G. *et al.* High-resolution transcriptome maps reveal strain-specific regulatory
769 features of multiple *Campylobacter jejuni* isolates. *PLoS Genet* **9**, e1003495,
770 doi:10.1371/journal.pgen.1003495 (2013).
- 771 47 Zanzoni, A., Spinelli, L., Braham, S. & Brun, C. Perturbed human sub-networks by
772 *Fusobacterium nucleatum* candidate virulence proteins. *Microbiome* **5**, 89,
773 doi:10.1186/s40168-017-0307-1 (2017).
- 774 48 Kapatral, V. *et al.* Genome analysis of *F. nucleatum* sub spp *vincentii* and its comparison
775 with the genome of *F. nucleatum* ATCC 25586. *Genome Res* **13**, 1180-1189,
776 doi:10.1101/gr.566003 (2003).
- 777 49 Desvaux, M., Khan, A., Beatson, S. A., Scott-Tucker, A. & Henderson, I. R. Protein secretion
778 systems in *Fusobacterium nucleatum*: genomic identification of Type 4 piliation and
779 complete Type V pathways brings new insight into mechanisms of pathogenesis.
780 *Biochimica et biophysica acta* **1713**, 92-112, doi:10.1016/j.bbamem.2005.05.002 (2005).
- 781 50 Umana, A. *et al.* Utilizing Whole *Fusobacterium* Genomes To Identify, Correct, and
782 Characterize Potential Virulence Protein Families. *J Bacteriol* **201**,
783 doi:10.1128/JB.00273-19 (2019).
- 784 51 Xu, M. *et al.* FadA from *Fusobacterium nucleatum* utilizes both secreted and nonsecreted
785 forms for functional oligomerization for attachment and invasion of host cells. *The*
786 *Journal of biological chemistry* **282**, 25000-25009, doi:10.1074/jbc.M611567200 (2007).
- 787 52 Kaplan, C. W., Lux, R., Haake, S. K. & Shi, W. The *Fusobacterium nucleatum* outer
788 membrane protein RadD is an arginine-inhibitable adhesin required for inter-species
789 adherence and the structured architecture of multispecies biofilm. *Molecular*
790 *microbiology* **71**, 35-47, doi:10.1111/j.1365-2958.2008.06503.x (2009).
- 791 53 Engevik, M. *et al.* *Fusobacterium nucleatum* adheres to *Clostridioides difficile* via the
792 RadD adhesin to enhance biofilm formation in intestinal mucus. *Gastroenterology*,
793 doi:10.1053/j.gastro.2020.11.034 (2020).
- 794 54 Doron, L. *et al.* Identification and characterization of fusolisins, the *Fusobacterium*
795 *nucleatum* autotransporter serine protease. *PLoS One* **9**, e111329,
796 doi:10.1371/journal.pone.0111329 (2014).
- 797 55 Kumar, A., Thotakura, P. L., Tiwary, B. K. & Krishna, R. Target identification in
798 *Fusobacterium nucleatum* by subtractive genomics approach and enrichment analysis of
799 host-pathogen protein-protein interactions. *BMC Microbiol* **16**, 84, doi:10.1186/s12866-
800 016-0700-0 (2016).
- 801 56 Storz, G., Wolf, Y. I. & Ramamurthi, K. S. Small proteins can no longer be ignored. *Annu*
802 *Rev Biochem* **83**, 753-777, doi:10.1146/annurev-biochem-070611-102400 (2014).

- 803 57 Cao, H., Ma, Q., Chen, X. & Xu, Y. DOOR: a prokaryotic operon database for genome
804 analyses and functional inference. *Brief Bioinform* **20**, 1568-1577,
805 doi:10.1093/bib/bbx088 (2019).
- 806 58 Casasanta, M. A. *et al.* A chemical and biological toolbox for Type Vd secretion:
807 Characterization of the phospholipase A1 autotransporter FplA from *Fusobacterium*
808 *nucleatum*. *The Journal of biological chemistry* **292**, 20240-20254,
809 doi:10.1074/jbc.M117.819144 (2017).
- 810 59 Loh, E., Righetti, F., Eichner, H., Twittenhoff, C. & Narberhaus, F. RNA Thermometers in
811 Bacterial Pathogens. *Microbiology spectrum* **6**, doi:10.1128/microbiolspec.RWR-0012-
812 2017 (2018).
- 813 60 McCown, P. J., Corbino, K. A., Stav, S., Sherlock, M. E. & Breaker, R. R. Riboswitch diversity
814 and distribution. *RNA (New York, N.Y.)* **23**, 995-1011, doi:10.1261/rna.061234.117
815 (2017).
- 816 61 Kalvari, I. *et al.* Rfam 13.0: shifting to a genome-centric resource for non-coding RNA
817 families. *Nucleic acids research* **46**, D335-D342, doi:10.1093/nar/gkx1038 (2018).
- 818 62 Winkler, W. C., Nahvi, A., Roth, A., Collins, J. A. & Breaker, R. R. Control of gene expression
819 by a natural metabolite-responsive ribozyme. *Nature* **428**, 281-286,
820 doi:10.1038/nature02362 (2004).
- 821 63 Johnsen, M., Christensen, T., Dennis, P. P. & Fiil, N. P. Autogenous control: ribosomal
822 protein L10-L12 complex binds to the leader sequence of its mRNA. *The EMBO Journal* **1**,
823 999-1004 (1982).
- 824 64 Yakhnin, H., Yakhnin, A. V. & Babitzke, P. Ribosomal protein L10(L12)₄ autoregulates
825 expression of the *Bacillus subtilis* rplJL operon by a transcription attenuation
826 mechanism. *Nucleic acids research* **43**, 7032-7043, doi:10.1093/nar/gkv628 (2015).
- 827 65 Bonner, E. R., D'Elia, J. N., Billips, B. K. & Switzer, R. L. Molecular recognition of pyr mRNA
828 by the *Bacillus subtilis* attenuation regulatory protein PyrR. *Nucleic acids research* **29**,
829 4851-4865, doi:10.1093/nar/29.23.4851 (2001).
- 830 66 Akopian, D., Shen, K., Zhang, X. & Shan, S. O. Signal recognition particle: an essential
831 protein-targeting machine. *Annu Rev Biochem* **82**, 693-721, doi:10.1146/annurev-
832 biochem-072711-164732 (2013).
- 833 67 Hartmann, E. & Hartmann, R. K. The enigma of ribonuclease P evolution. *Trends Genet*
834 **19**, 561-569, doi:10.1016/j.tig.2003.08.007 (2003).
- 835 68 Wassarman, K. M. 6S RNA, a Global Regulator of Transcription. *Microbiology spectrum* **6**,
836 doi:10.1128/microbiolspec.RWR-0019-2018 (2018).
- 837 69 Wehner, S., Damm, K., Hartmann, R. K. & Marz, M. Dissemination of 6S RNA among
838 bacteria. *RNA biology* **11**, 1467-1478, doi:10.4161/rna.29894 (2014).
- 839 70 Cochrane, K. *et al.* Complete genome sequences and analysis of the *Fusobacterium*
840 *nucleatum* subspecies *animalis* 7-1 bacteriophage ϕ Funu1 and ϕ Funu2. *Anaerobe* **38**,
841 125-129, doi:10.1016/j.anaerobe.2015.10.013 (2016).

- 842 71 Richter, H. *et al.* Characterization of CRISPR RNA processing in *Clostridium*
843 *thermocellum* and *Methanococcus maripaludis*. *Nucleic acids research* **40**, 9887-9896,
844 doi:10.1093/nar/gks737 (2012).
- 845 72 Millman, A. *et al.* Bacterial Retrons Function In Anti-Phage Defense. *Cell*,
846 doi:10.1016/j.cell.2020.09.065 (2020).
- 847 73 Melamed, S., Adams, P. P., Zhang, A., Zhang, H. & Storz, G. RNA-RNA Interactomes of ProQ
848 and Hfq Reveal Overlapping and Competing Roles. *Mol Cell* **77**, 411-425 e417,
849 doi:10.1016/j.molcel.2019.10.022 (2020).
- 850 74 Smirnov, A. *et al.* Grad-seq guides the discovery of ProQ as a major small RNA-binding
851 protein. *Proc Natl Acad Sci U S A* **113**, 11591-11596, doi:10.1073/pnas.1609981113
852 (2016).
- 853 75 Bak, G. *et al.* Identification of novel sRNAs involved in biofilm formation, motility, and
854 fimbriae formation in *Escherichia coli*. *Scientific reports* **5**, 15287,
855 doi:10.1038/srep15287 (2015).
- 856 76 Loh, E. *et al.* A trans-acting riboswitch controls expression of the virulence regulator
857 PrfA in *Listeria monocytogenes*. *Cell* **139**, 770-779, doi:10.1016/j.cell.2009.08.046
858 (2009).
- 859 77 Koonin, E. V., Makarova, K. S. & Wolf, Y. I. Evolutionary Genomics of Defense Systems in
860 Archaea and Bacteria. *Annu Rev Microbiol* **71**, 233-261, doi:10.1146/annurev-micro-
861 090816-093830 (2017).
- 862 78 Fagan, R. P. & Fairweather, N. F. *Clostridium difficile* has two parallel and essential Sec
863 secretion systems. *The Journal of biological chemistry* **286**, 27483-27493,
864 doi:10.1074/jbc.M111.263889 (2011).
- 865 79 Mann, M., Wright, P. R. & Backofen, R. IntaRNA 2.0: enhanced and customizable
866 prediction of RNA-RNA interactions. *Nucleic acids research* **45**, W435-W439,
867 doi:10.1093/nar/gkx279 (2017).
- 868 80 Wu, C. *et al.* Forward Genetic Dissection of Biofilm Development by *Fusobacterium*
869 *nucleatum*: Novel Functions of Cell Division Proteins FtsX and EnvC. *mBio* **9**,
870 doi:10.1128/mBio.00360-18 (2018).
- 871 81 Copenhagen-Glazer, S. *et al.* Fap2 of *Fusobacterium nucleatum* is a galactose-
872 inhibitable adhesin involved in coaggregation, cell adhesion, and preterm birth. *Infect*
873 *Immun* **83**, 1104-1113, doi:10.1128/IAI.02838-14 (2015).
- 874 82 Brown, S. P., Cornforth, D. M. & Mideo, N. Evolution of virulence in opportunistic
875 pathogens: generalism, plasticity, and control. *Trends in microbiology* **20**, 336-342,
876 doi:10.1016/j.tim.2012.04.005 (2012).
- 877 83 Bayley, D. P., Rocha, E. R. & Smith, C. J. Analysis of *cepA* and other *Bacteroides fragilis*
878 genes reveals a unique promoter structure. *FEMS microbiology letters* **193**, 149-154,
879 doi:10.1111/j.1574-6968.2000.tb09417.x (2000).
- 880 84 Ryan, D., Jenniches, L., Reichardt, S., Barquist, L. & Westermann, A. J. A high-resolution
881 transcriptome map identifies small RNA regulation of metabolism in the gut microbe
882 *Bacteroides thetaiotaomicron*. *Nat Commun* **11**, 3557, doi:10.1038/s41467-020-17348-
883 5 (2020).

- 884 85 Jackson, C. A. *et al.* A consensus Porphyromonas gingivalis promoter sequence. *FEMS*
885 *microbiology letters* **186**, 133-138, doi:10.1111/j.1574-6968.2000.tb09094.x (2000).
- 886 86 Michaux, C. *et al.* Single-Nucleotide RNA Maps for the Two Major Nosocomial Pathogens
887 Enterococcus faecalis and Enterococcus faecium. *Front Cell Infect Microbiol* **10**, 600325,
888 doi:10.3389/fcimb.2020.600325 (2020).
- 889 87 Olejniczak, M. & Storz, G. ProQ/FinO-domain proteins: another ubiquitous family of RNA
890 matchmakers? *Molecular microbiology* **104**, 905-915, doi:10.1111/mmi.13679 (2017).
- 891 88 Holmqvist, E. & Vogel, J. RNA-binding proteins in bacteria. *Nature reviews. Microbiology*
892 **16**, 601-615, doi:10.1038/s41579-018-0049-5 (2018).
- 893 89 Zheng, J. J., Perez, A. J., Tsui, H. T., Massidda, O. & Winkler, M. E. Absence of the KhpA and
894 KhpB (JAG/EloR) RNA-binding proteins suppresses the requirement for PBP2b by
895 overproduction of FtsA in Streptococcus pneumoniae D39. *Molecular microbiology* **106**,
896 793-814, doi:10.1111/mmi.13847 (2017).
- 897 90 Lamm-Schmidt, V. *et al.* Grad-seq identifies KhpB as a global RNA-binding protein in
898 Clostridioides difficile that regulates toxin production. *microLife* **2**,
899 doi:10.1093/femsml/uqab004 (2021).
- 900 91 Hör, J. *et al.* Grad-seq in a Gram-positive bacterium reveals exonucleolytic sRNA
901 activation in competence control. *Embo j* **39**, e103852, doi:10.15252/embj.2019103852
902 (2020).
- 903 92 Altuvia, S., Weinstein-Fischer, D., Zhang, A., Postow, L. & Storz, G. A small, stable RNA
904 induced by oxidative stress: role as a pleiotropic regulator and antimutator. *Cell* **90**, 43-
905 53, doi:10.1016/s0092-8674(00)80312-8 (1997).
- 906 93 Pfeiffer, V. *et al.* A small non-coding RNA of the invasion gene island (SPI-1) represses
907 outer membrane protein synthesis from the Salmonella core genome. *Molecular*
908 *microbiology* **66**, 1174-1191, doi:10.1111/j.1365-2958.2007.05991.x (2007).
- 909 94 Guisbert, E., Rhodius, V. A., Ahuja, N., Witkin, E. & Gross, C. A. Hfq modulates the sigmaE-
910 mediated envelope stress response and the sigma32-mediated cytoplasmic stress
911 response in Escherichia coli. *J Bacteriol* **189**, 1963-1973, doi:10.1128/JB.01243-06
912 (2007).
- 913 95 Vanderpool, C. K. & Gottesman, S. The novel transcription factor SgrR coordinates the
914 response to glucose-phosphate stress. *J Bacteriol* **189**, 2238-2248,
915 doi:10.1128/JB.01689-06 (2007).
- 916 96 Nejman, D. *et al.* The human tumor microbiome is composed of tumor type-specific
917 intracellular bacteria. *Science (New York, N.Y.)* **368**, 973-980,
918 doi:10.1126/science.aay9189 (2020).
- 919 97 Swidsinski, A. *et al.* Acute appendicitis is characterised by local invasion with
920 Fusobacterium nucleatum/necrophorum. *Gut* **60**, 34-40, doi:10.1136/gut.2009.191320
921 (2011).
- 922 98 Han, X. Y. *et al.* Fusobacterial brain abscess: a review of five cases and an analysis of
923 possible pathogenesis. *J Neurosurg* **99**, 693-700, doi:10.3171/jns.2003.99.4.0693
924 (2003).

- 925 99 Gregory, S. W., Boyce, T. G., Larson, A. N., Patel, R. & Jackson, M. A. Fusobacterium
926 nucleatum Osteomyelitis in 3 Previously Healthy Children: A Case Series and Review of
927 the Literature. *J Pediatric Infect Dis Soc* **4**, e155-159, doi:10.1093/jpids/piv052 (2015).
- 928 100 Truant, A. L., Menge, S., Milliorn, K., Lairscey, R. & Kelly, M. T. Fusobacterium nucleatum
929 pericarditis. *J Clin Microbiol* **17**, 349-351, doi:10.1128/JCM.17.2.349-351.1983 (1983).
- 930 101 Altshuler, G. & Hyde, S. Clinicopathologic considerations of fusobacteria
931 chorioamnionitis. *Acta Obstet Gynecol Scand* **67**, 513-517,
932 doi:10.3109/00016348809029862 (1988).
- 933 102 Toussi, D. N., Liu, X. & Massari, P. The FomA porin from Fusobacterium nucleatum is a
934 Toll-like receptor 2 agonist with immune adjuvant activity. *Clin Vaccine Immunol* **19**,
935 1093-1101, doi:10.1128/CVI.00236-12 (2012).
- 936 103 Westermann, A. J. *et al.* Dual RNA-seq unveils noncoding RNA functions in host-pathogen
937 interactions. *Nature* **529**, 496-501, doi:10.1038/nature16547 (2016).
- 938 104 Imdahl, F., Vafadarnejad, E., Homberger, C., Saliba, A. E. & Vogel, J. Single-cell RNA-
939 sequencing reports growth-condition-specific global transcriptomes of individual
940 bacteria. *Nat Microbiol*, doi:10.1038/s41564-020-0774-1 (2020).
- 941 105 Blattman, S. B., Jiang, W., Oikonomou, P. & Tavazoie, S. Prokaryotic single-cell RNA
942 sequencing by in situ combinatorial indexing. *Nat Microbiol* **5**, 1192-1201,
943 doi:10.1038/s41564-020-0729-6 (2020).
- 944 106 Ji, Y. *et al.* Identification of critical staphylococcal genes using conditional phenotypes
945 generated by antisense RNA. *Science (New York, N.Y.)* **293**, 2266-2269,
946 doi:10.1126/science.1063566 (2001).
- 947 107 Blomberg, P., Wagner, E. G. & Nordstrom, K. Control of replication of plasmid R1: the
948 duplex between the antisense RNA, CopA, and its target, CopT, is processed specifically
949 in vivo and in vitro by RNase III. *Embo j* **9**, 2331-2340 (1990).
- 950 108 Berezikov, E. *et al.* Diversity of microRNAs in human and chimpanzee brain. *Nature*
951 *genetics* **38**, 1375-1377, doi:10.1038/ng1914 (2006).
- 952 109 Förstner, K. U., Vogel, J. & Sharma, C. M. READemption-a tool for the computational
953 analysis of deep-sequencing-based transcriptome data. *Bioinformatics* **30**, 3421-3423,
954 doi:10.1093/bioinformatics/btu533 (2014).
- 955 110 Otto, C., Stadler, P. F. & Hoffmann, S. Fast and sensitive mapping of bisulfite-treated
956 sequencing data. *Bioinformatics* **28**, 1698-1704, doi:10.1093/bioinformatics/bts254
957 (2012).
- 958 111 Kingsford, C. L., Ayanbule, K. & Salzberg, S. L. Rapid, accurate, computational discovery
959 of Rho-independent transcription terminators illuminates their relationship to DNA
960 uptake. *Genome biology* **8**, R22, doi:10.1186/gb-2007-8-2-r22 (2007).
- 961 112 Quinlan, A. R. BEDTools: The Swiss-Army Tool for Genome Feature Analysis. *Current*
962 *protocols in bioinformatics* **47**, 11.12.11-34, doi:10.1002/0471250953.bi1112s47
963 (2014).

- 964 113 Haake, S. K., Yoder, S. C., Attarian, G. & Podkaminer, K. Native plasmids of *Fusobacterium*
965 *nucleatum*: characterization and use in development of genetic systems. *J Bacteriol* **182**,
966 1176-1180, doi:10.1128/jb.182.4.1176-1180.2000 (2000).
- 967 114 Knoke, L. R. *et al.* Agrobacterium tumefaciens Small Lipoprotein Atu8019 Is Involved in
968 Selective Outer Membrane Vesicle (OMV) Docking to Bacterial Cells. *Front Microbiol* **11**,
969 1228, doi:10.3389/fmicb.2020.01228 (2020).
- 970 115 Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized
971 p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol*
972 **26**, 1367-1372, doi:10.1038/nbt.1511 (2008).
- 973 116 Drozdetskiy, A., Cole, C., Procter, J. & Barton, G. J. JPred4: a protein secondary structure
974 prediction server. *Nucleic acids research* **43**, W389-394, doi:10.1093/nar/gkv332
975 (2015).
- 976 117 Almagro Armenteros, J. J. *et al.* SignalP 5.0 improves signal peptide predictions using
977 deep neural networks. *Nat Biotechnol* **37**, 420-423, doi:10.1038/s41587-019-0036-z
978 (2019).
- 979 118 Lorenz, R. *et al.* ViennaRNA Package 2.0. *Algorithms for molecular biology : AMB* **6**, 26,
980 doi:10.1186/1748-7188-6-26 (2011).

981
982

983 **Author Contribution Statement**

984 F.P., C.T. and Y.Z. conducted experiments. F.P. performed data analysis. F.P. and J.V.
985 designed research. L.B. set up the web browser. J.V. directed research. F.P., F.F. and J.V.
986 wrote the manuscript.

987

988 **Competing Interest Statement**

989 The authors declare no competing interests.

990

991 **Figure Legends**

992 **Figure 1: dRNA-seq for *F. nucleatum* subsp. *nucleatum***

993 **a**, Overview of analyzed growth conditions (early (E), mid-exponential (M) and early
994 stationary (S) phase) and experimental workflow for transcriptome analysis via dRNA-
995 seq. Genome-wide read distribution for *F. nucleatum* subsp. *nucleatum* ATCC 25586 are
996 shown followed by the validation of the previously annotated TSS for *tnaA*. Growth data
997 are represented by the mean (+/- standard deviation) from three biological replicates.
998 **b**, Venn diagram showing the number of detected TSS for each class. The lower panel
999 shows TSS classification based upon expression strength and genomic location. **c**,
1000 Analysis of promoter regions associated with detected TSSs using the MEME⁴⁵
1001 suite identified a promoter motif in ~93% of analyzed pTSS. An extended -10 box and
1002 the -35 box that are separated by an AT-rich region are indicated. **d**, Length distribution
1003 and corresponding occurrences of all 5'UTRs associated with pTSS (black) and sTSS

1004 (red). A consensus Shine Dalgarno sequence was predicted using MEME analysis. The
1005 average distance from the start codon is indicated.
1006

1007 **Figure 2: Transcriptome features of known virulence factors and prediction of**
1008 **small proteins in *F. nucleatum* subsp. *nucleatum*.**

1009 **a**, Genomic context and transcriptome features for representative examples of known
1010 virulence-associated genes. Rho-independent terminators were predicted with
1011 ANNOgesic. **b**, Conservation analysis combined with TSS prediction uncovers the small
1012 protein candidate FspC3 in the intergenic region upstream of FN0239. Genomic
1013 alignment for representative strains of different fusobacteria harbouring a *fspC3*
1014 sequence (FNN = *F. n. subsp. nucleatum*; FNA = *F. n. subsp. animalis*; FNP = *F. n. subsp.*
1015 *polymorphum*; FNV = *F. n. subsp. vincentii*; FuH = *F. hwasookii*; FuP = *F. periodonticum*).
1016 For protein alignment, protein sequences from all available annotated genomes of the
1017 above fusobacteria were used. The web-application of jpred 4¹¹⁶ and SignalP
1018 (5.0)¹¹⁷ was used to predict the secondary structure and signal peptide respectively.
1019

1020 **Figure 3: Identification of core noncoding RNAs and an active CRISPR-Cas system**
1021 **in *F. nucleatum* subsp. *nucleatum***

1022 **a**, Expression profiling of 6S RNA, 4.5S RNA, tmRNA and M1 RNA of RNase P across the
1023 different growth stages by northern blot. **b**, Read distribution for the 6S RNA detects an
1024 antisense TSS supporting the transcription of the pRNA. **c**, Secondary structure
1025 prediction of the putative 6S RNA shows a two-handle stem-loop structure with an
1026 internal bulge region commonly found in known 6S RNAs. The TSS associated with the
1027 identified pRNA (blue) is indicated with an arrow. **d**, Northern blot validation for the
1028 processing of the CRISPR array by probing for the overlapping region between
1029 individual spacer and repeat pairs. The results show generation of single spacer-repeat
1030 pairs of ~67nt increasing towards stationary phase, and also larger fragments
1031 indicating a more complex processing of the array. Rho-independent terminator was
1032 predicted via ANNOgesic.
1033

1034 **Figure 4: The small noncoding RNA landscape in *Fusobacterium* species**

1035 **a**, Distribution of all predicted TSS and sRNAs across the Fnn genome. **b**, Shown is the
1036 conservation analysis for all validated candidates within 36 complete genomes of *F.*
1037 *nucleatum* strains and related species in the *Fusobacterium* genus. For each strain,
1038 sRNAs are considered to be conserved if they display $\geq 75\%$ nucleotide identity and
1039 were not shorter than the 75% of the sRNAs length in the reference strain. An asterisk
1040 (*) marks sRNA candidate which overlap with riboswitch predictions but detection of a
1041 stable fragment by northern blot analysis indicate potential dual functions. Grey boxes
1042 indicate that the ncRNAs did not meet the required criteria but were predicted via
1043 RFAM. Purple ncRNAs were only identified when comparing genomic synteny in
1044 addition to the secondary structure of these regions. **c**, Northern blot validation of
1045 predicted sRNAs in three different growth phases. The sRNA candidates are classified
1046 into established classes of intergenic, 5'UTR or 3'UTR-derived or antisense sRNAs. Rho-
1047 independent terminators were predicted by ANNOgesic.
1048

1049 **Figure 5: *FoxI* is an oxygen-induced conserved sRNA**

1050 **a**, Comparison of genome synteny for *FoxI* in *F. nucleatum* subsp. *nucleatum* (FNN),
1051 subsp. *polymorphum* (FNP), subsp. *vincentii* (FNV), subsp. *animalis* (FNA) as well as
1052 *Fusobacterium periodonticum* (FuP) and *F. hwasookii* (FuH) reveals the conserved

1053 genomic localization of the sRNA between the tryptophanase subunit B (*trpB*) and the
1054 ribosomal small subunit methyltransferase B (*rsmB*). The *trpB* gene is absent in all FNV
1055 strains. **b**, Expression profiling of FoxI by Northern blot in three different growth phases
1056 (E – early exponential, M – mid exponential, S - stationary). **c**, Alignment of FoxI and its
1057 upstream region highlights the strong sequence conservation for the sRNA as well as
1058 the promoter region. A predicted terminator loop is indicated. **d**, Predicted secondary
1059 structure of FoxI using RNAfold¹¹⁸. The nucleotide exchanges generating FoxI-3C are
1060 shown. **e**, Expression profiling of FoxI by northern blot analysis under different stress
1061 conditions shows FoxI to be highly upregulated upon 20 min. of exposure to oxygen.
1062

1063 **Figure 6: Overexpression of FoxI identifies the OMP FomA as a potential target of**
1064 **the sRNA**

1065 **a**, Schematic representation of the shuttle vector pEcoFus used for sRNA
1066 overexpression. The vector is derived from pRPF185⁷⁸ and carries a plasmid origin of
1067 replication functioning in *F. nucleatum* (OriFn). Expression of the sRNA is driven by the
1068 4.5S RNA promoter (P_{4.5S RNA}). Northern blot validation for the overexpression of FoxI
1069 and four additional sRNAs compared to the wildtype (WT) and the empty vector control
1070 (ctrl.) which carries a short nonsense stretch after the promoter. From top to bottom,
1071 the panel shows probing for: FoxI, FunR7, FunR12, FunR16 and FunR47. **b**, Denaturing
1072 SDS page and western blot analysis of subcellular fractionation of *Fnn* carrying the
1073 empty vector control, the overexpression vector for FoxI or FoxI-3C. Equal OD units for
1074 the total protein and cytosolic fraction were collected from mid-exponential phase
1075 cultures and 10x the amount was loaded for the inner membrane (IM) and outer
1076 membrane (OM) fraction to ensure proper visualization after coomassie staining.
1077 Western blot analysis was carried out loading half the amounts prior to detection of
1078 FomA using an anti-FomA antibody. **c**, Results of LC-MS/MS analysis comparing the
1079 ratios for label free quantification (LFQ) of the overexpression of FoxI or FoxI-3C to the
1080 empty vector control. Shown are only the proteins detected across all samples in the
1081 size range of 35-55 kDa. **d**, Base-pairing between the 5' region of *fomA* and the linear
1082 region FoxI as predicted by IntaRNA. The start codon of *fomA* (red) as well as the
1083 mutated region in FoxI-3C (grey) are indicated. **e**, Alignment of the 5'UTR and proximal
1084 coding region of *fomA* from representative strains of the different fusobacterial strains
1085 (FNN = *F. n. subsp. nucleatum*; FNA = *F. n. subsp. animalis*; FNP = *F. n. subsp.*
1086 *polymorphum*; FNV = *F. n. subsp. vincentii*; FuH = *F. hwasookii*; FuP = *F. periodonticum*).
1087 The predicted binding site of FoxI as well as the TSS and AUG start codon are indicated.